Woodcock: High Drug Prices Changing Drug Development Debate

By David Roza / November 15, 2018 at 2:41 PM
FDA drug center director Janet Woodcock said rising drug prices are changing the nature of debate surrounding the agency’s drug development requirements. Woodcock said critics have traditionally called out the process as either being too slow or too fast for getting new drugs to market, but the rise in drug prices has sparked a new debate about whether the cost and the unresolved risks of a new drug should be considered in deciding whether the drug provides a societal benefit...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.